These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

302 related items for PubMed ID: 37515462

  • 1. Cost-effectiveness of integrated treatment for hepatitis C virus (HCV) among people who inject drugs in Norway: An economic evaluation of the INTRO-HCV trial.
    Lim AG, Aas CF, Çağlar ES, Vold JH, Fadnes LT, Vickerman P, Johansson KA.
    Addiction; 2023 Dec; 118(12):2424-2439. PubMed ID: 37515462
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness of mass screening for Hepatitis C virus among all inmates in an Irish prison.
    Ward Z, Mafirakureva N, Stone J, Keevans M, Betts-Symonds G, Crowley D, McHugh T, Avramovic G, Lambert JS, Vickerman P.
    Int J Drug Policy; 2021 Oct; 96():103394. PubMed ID: 34412938
    [Abstract] [Full Text] [Related]

  • 3. An intensive model of care for hepatitis C virus screening and treatment with direct-acting antivirals in people who inject drugs in Nairobi, Kenya: a model-based cost-effectiveness analysis.
    Mafirakureva N, Stone J, Fraser H, Nzomukunda Y, Maina A, Thiong'o AW, Kizito KW, Mucara EWK, González Diaz CI, Musyoki H, Mundia B, Cherutich P, Nyakowa M, Lizcano J, Chhun N, Kurth A, Akiyama MJ, Waruiru W, Bhattacharjee P, Cleland C, Donchuk D, Luhmann N, Loarec A, Maman D, Walker J, Vickerman P.
    Addiction; 2022 Feb; 117(2):411-424. PubMed ID: 34184794
    [Abstract] [Full Text] [Related]

  • 4. Cost effectiveness of simplified HCV screening-and-treatment interventions for people who inject drugs in Dar-es-Salaam, Tanzania.
    Mohamed Z, Scott N, Nayagam S, Rwegasha J, Mbwambo J, Thursz MR, Brown AS, Hellard M, Lemoine M.
    Int J Drug Policy; 2022 Jan; 99():103458. PubMed ID: 34624732
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of the HepCATT intervention in specialist drug clinics to improve case-finding and engagement with HCV treatment for people who inject drugs in England.
    Ward Z, Reynolds R, Campbell L, Martin NK, Harrison G, Irving W, Hickman M, Vickerman P.
    Addiction; 2020 Aug; 115(8):1509-1521. PubMed ID: 31984606
    [Abstract] [Full Text] [Related]

  • 6. Integrated treatment of hepatitis C virus infection among people who inject drugs: study protocol for a randomised controlled trial (INTRO-HCV).
    Fadnes LT, Aas CF, Vold JH, Ohldieck C, Leiva RA, Chalabianloo F, Skurtveit S, Lygren OJ, Dalgård O, Vickerman P, Midgard H, Løberg EM, Johansson KA, INTRO-HCV Study Group.
    BMC Infect Dis; 2019 Nov 08; 19(1):943. PubMed ID: 31703669
    [Abstract] [Full Text] [Related]

  • 7. Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France.
    Cousien A, Tran VC, Deuffic-Burban S, Jauffret-Roustide M, Mabileau G, Dhersin JS, Yazdanpanah Y.
    J Viral Hepat; 2018 Oct 08; 25(10):1197-1207. PubMed ID: 29660211
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of Direct Antiviral Agents for Hepatitis C Virus Infection and a Combined Intervention of Syringe Access and Medication-assisted Therapy for Opioid Use Disorders in an Injection Drug Use Population.
    Stevens ER, Nucifora KA, Hagan H, Jordan AE, Uyei J, Khan B, Dombrowski K, des Jarlais D, Braithwaite RS.
    Clin Infect Dis; 2020 Jun 10; 70(12):2652-2662. PubMed ID: 31400755
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of hepatitis C virus (HCV) elimination strategies among people who inject drugs (PWID) in Tijuana, Mexico.
    Marquez LK, Fleiz C, Burgos JL, Cepeda JA, McIntosh C, Garfein RS, Kiene SM, Brodine S, Strathdee SA, Martin NK.
    Addiction; 2021 Oct 10; 116(10):2734-2745. PubMed ID: 33620750
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of treating chronic hepatitis C virus with direct-acting antivirals in people who inject drugs in Australia.
    Scott N, Iser DM, Thompson AJ, Doyle JS, Hellard ME.
    J Gastroenterol Hepatol; 2016 Apr 10; 31(4):872-82. PubMed ID: 26514998
    [Abstract] [Full Text] [Related]

  • 11. Integrated treatment of hepatitis C virus infection among people who inject drugs: A multicenter randomized controlled trial (INTRO-HCV).
    Fadnes LT, Aas CF, Vold JH, Leiva RA, Ohldieck C, Chalabianloo F, Skurtveit S, Lygren OJ, Dalgård O, Vickerman P, Midgard H, Løberg EM, Johansson KA, INTRO-HCV Study Group.
    PLoS Med; 2021 Jun 10; 18(6):e1003653. PubMed ID: 34061883
    [Abstract] [Full Text] [Related]

  • 12. Economic evaluation of the Hepatitis C virus elimination program in the country of Georgia, 2015 to 2017.
    Tskhomelidze I, Shadaker S, Kuchuloria T, Gvinjilia L, Butsashvili M, Nasrullah M, Gabunia T, Gamkrelidze A, Getia V, Sharvadze L, Tsertsvadze T, Zarqua J, Tsanava S, Handanagic S, Armstrong PA, Averhoff F, Vickerman P, Walker JG.
    Liver Int; 2023 Mar 10; 43(3):558-568. PubMed ID: 36129625
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of scaling-up HCV prevention and treatment in the United States for people who inject drugs.
    Barbosa C, Fraser H, Hoerger TJ, Leib A, Havens JR, Young A, Kral A, Page K, Evans J, Zibbell J, Hariri S, Vellozzi C, Nerlander L, Ward JW, Vickerman P.
    Addiction; 2019 Dec 10; 114(12):2267-2278. PubMed ID: 31307116
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness of pharmacy-led versus conventionally delivered antiviral treatment for hepatitis C in patients receiving opioid substitution therapy: An economic evaluation alongside a pragmatic cluster randomised trial.
    Myring G, Lim AG, Hollingworth W, McLeod H, Beer L, Vickerman P, Hickman M, Radley A, Dillon JF.
    J Infect; 2022 Dec 10; 85(6):676-682. PubMed ID: 36170895
    [Abstract] [Full Text] [Related]

  • 15. Treating Hepatitis C Before Total Knee Arthroplasty is Cost-Effective: A Markov Analysis.
    Kalyanasundaram G, Feng JE, Congiusta F, Iorio R, DiCaprio M, Anoushiravani AA.
    J Arthroplasty; 2024 Feb 10; 39(2):307-312. PubMed ID: 37604270
    [Abstract] [Full Text] [Related]

  • 16. Evaluating the cost-effectiveness of existing needle and syringe programmes in preventing hepatitis C transmission in people who inject drugs.
    Sweeney S, Ward Z, Platt L, Guinness L, Hickman M, Hope V, Maher L, Iversen J, Hutchinson SJ, Smith J, Ayres R, Hainey I, Vickerman P.
    Addiction; 2019 Mar 10; 114(3):560-570. PubMed ID: 30674091
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of Hepatitis C Virus Treatment Models for People Who Inject Drugs in Opioid Agonist Treatment Programs.
    Gutkind S, Schackman BR, Morgan JR, Leff JA, Agyemang L, Murphy SM, Akiyama MJ, Norton BL, Litwin AH, Linas BP.
    Clin Infect Dis; 2020 Mar 17; 70(7):1397-1405. PubMed ID: 31095683
    [Abstract] [Full Text] [Related]

  • 18. Direct-Acting Antiviral Agents for Patients With Hepatitis C Virus Genotype 1 Infection Are Cost-Saving.
    Chhatwal J, He T, Hur C, Lopez-Olivo MA.
    Clin Gastroenterol Hepatol; 2017 Jun 17; 15(6):827-837.e8. PubMed ID: 27650326
    [Abstract] [Full Text] [Related]

  • 19. Opportunistic treatment of hepatitis C virus infection (OPPORTUNI-C): study protocol for a pragmatic stepped wedge cluster randomized trial of immediate versus outpatient treatment initiation among hospitalized people who inject drugs.
    Midgard H, Finbråten AK, Malme KB, Berg-Pedersen RM, Tanum L, Olsen IC, Bjørnestad R, Dalgard O.
    Trials; 2020 Jun 15; 21(1):524. PubMed ID: 32539853
    [Abstract] [Full Text] [Related]

  • 20. Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysis.
    Martin NK, Vickerman P, Brew IF, Williamson J, Miners A, Irving WL, Saksena S, Hutchinson SJ, Mandal S, O'Moore E, Hickman M.
    Hepatology; 2016 Jun 15; 63(6):1796-808. PubMed ID: 26864802
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.